

# Andrew C Bishop

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7436365/publications.pdf>

Version: 2024-02-01

11  
papers

397  
citations

1307366

7  
h-index

1474057

9  
g-index

13  
all docs

13  
docs citations

13  
times ranked

815  
citing authors

#	ARTICLE	IF	CITATIONS
1	Breath biomarkers of insulin resistance in pre-diabetic Hispanic adolescents with obesity. <i>Scientific Reports</i> , 2022, 12, 339.	1.6	8
2	Human GDPD3 overexpression promotes liver steatosis by increasing lysophosphatidic acid production and fatty acid uptake. <i>Journal of Lipid Research</i> , 2020, 61, 1075-1086.	2.0	13
3	Nonhuman primate breath volatile organic compounds associate with developmental programming and cardio-metabolic status. <i>Journal of Breath Research</i> , 2018, 12, 036016.	1.5	11
4	High-resolution gas chromatography/mass spectrometry metabolomics of non-human primate serum. <i>Rapid Communications in Mass Spectrometry</i> , 2018, 32, 1497-1506.	0.7	33
5	Abstract 426: Atherosclerotic Risk Factors Correlate with Carotid Intimal Media Thickness in Participants of the Childhood Obesity Study in South Texas: Preliminary Results. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, .	1.1	0
6	Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. <i>Nature</i> , 2015, 523, 347-351.	13.7	221
7	Glycerophosphocholine Utilization by <i>Candida albicans</i> . <i>Journal of Biological Chemistry</i> , 2013, 288, 33939-33952.	1.6	35
8	Zap1 Control of Cell-Cell Signaling in <i>Candida albicans</i> Biofilms. <i>Eukaryotic Cell</i> , 2011, 10, 1448-1454.	3.4	60
9	Robust Utilization of Phospholipase-Generated Metabolites, Glycerophosphodiesteres, by <i>Candida albicans</i> : Role of the CaGit1 Permease. <i>Eukaryotic Cell</i> , 2011, 10, 1618-1627.	3.4	12
10	Neurofibromin Homologs Ira1 and Ira2 Affect Glycerophosphoinositol Production and Transport in <i>Saccharomyces cerevisiae</i> . <i>Eukaryotic Cell</i> , 2009, 8, 1808-1811.	3.4	3
11	Recent Advances in Targeting Clinical Volatile Organic Compounds (VOC). , 0, , .		1